Phase IIb trial investigating the efficacy of KRN 5500 in patients with chronic chemotherapy-induced neuropathic pain.

Trial Profile

Phase IIb trial investigating the efficacy of KRN 5500 in patients with chronic chemotherapy-induced neuropathic pain.

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs KRN 5500 (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2012 Planned initiation date changed from 1 Jul 2010 to 1 Jun 2012.
    • 25 Mar 2010 This trial is expected to be initiated in the second half of 2010 according to a Dara BioScience media release.
    • 27 Nov 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top